Literature DB >> 29592980

Metastatic pheochromocytoma in MEN 2A: A rare association.

Rimesh Pal1, Ashu Rastogi1, Santosh Kumar2, Anil Bhansali1.   

Abstract

A 45-year-old woman was diagnosed as having multiple endocrine neoplasia type 2A in 2014. She had bilateral pheochromocytoma, medullary thyroid carcinoma and biopsy-proven cutaneous lichen amyloidosis in the interscapular area. She underwent bilateral adrenalectomy; following which, she achieved clinical and biochemical remission. She was planned for total thyroidectomy at a later date; however, she was lost to follow-up. She presented to us again in December 2016 with abdominal pain. Examination revealed hypertension with postural drop. Positron emission tomography scan showed Ga68 and fluorodeoxyglucose (FDG)-avid suprarenal, hepatic, peritoneal and mesenteric masses with abdominal lymph nodes. Twenty-four-hour urinary metanephrines/normetanephrines were elevated. Serum calcitonin was as high as it was 2-1/2 years ago. Ultrasonography-guided fine-needle aspiration cytology (FNAC) from the liver mass revealed neuroendocrine cells that did not stain for calcitonin. Hence, a diagnosis of metastatic pheochromocytoma was made. She underwent total thyroidectomy and was started on cyclophosphamide, vincristine, dacarbazine-based chemotherapy regimen. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  adrenal disorders; endocrine cancer; thyroid disease

Mesh:

Year:  2018        PMID: 29592980      PMCID: PMC5878377          DOI: 10.1136/bcr-2017-222758

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Pheochromocytoma: unusual presentation of a rare disease.

Authors:  Ashraf Hamdan; Dania Hirsch; Pnina Green; Avivit Neumann; Tamara Drozd; Yair Molad
Journal:  Isr Med Assoc J       Date:  2002-10       Impact factor: 0.892

2.  Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.

Authors:  H Namba; H Kondo; S Yamashita; H Kimura; N Yokoyama; M Tsuruta; A Sato; M Izumi; H Kinoshita; S Hakariya
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

3.  Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant pheochromocytoma and ganglioneuroma.

Authors:  S Gullu; A Gursoy; M F Erdogan; S Dizbaysak; G Erdogan; N Kamel
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

4.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

5.  Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group.

Authors:  E Modigliani; H M Vasen; K Raue; H Dralle; A Frilling; R G Gheri; M L Brandi; E Limbert; B Niederle; L Forgas
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

6.  Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases.

Authors:  S Casanova; M Rosenberg-Bourgin; D Farkas; C Calmettes; N Feingold; H M Heshmati; R Cohen; B Conte-Devolx; P J Guillausseau; C Houdent
Journal:  Clin Endocrinol (Oxf)       Date:  1993-05       Impact factor: 3.478

7.  Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma.

Authors:  Andreas Machens; Hans-Jürgen Holzhausen; Christine Lautenschläger; Phuong Nguyen Thanh; Henning Dralle
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

8.  Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.

Authors:  Anne Laure Giraudet; Abir Al Ghulzan; Anne Aupérin; Sophie Leboulleux; Ahmed Chehboun; Frédéric Troalen; Clarisse Dromain; Jean Lumbroso; Eric Baudin; Martin Schlumberger
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

9.  The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2.

Authors:  Sonali Thosani; Montserrat Ayala-Ramirez; Lynn Palmer; Mimi I Hu; Thereasa Rich; Robert F Gagel; Gilbert Cote; Steven G Waguespack; Mouhammed Amir Habra; Camilo Jimenez
Journal:  J Clin Endocrinol Metab       Date:  2013-09-12       Impact factor: 5.958

10.  A case of Sipple's syndrome with malignant pheochromocytoma treated with 131I-metaiodobenzyl guanidine and a combined chemotherapy with cyclophosphamide, vincristine and dacarbazine.

Authors:  M Sasaki; T Iwaoka; J Yamauchi; H Tokunaga; S Naomi; J Inoue; S Oishi; T Umeda; T Sato
Journal:  Endocr J       Date:  1994-04       Impact factor: 2.349

View more
  2 in total

1.  A Case of 123I-Metaiodobenzylguanidine Scintigraphy-Negative Pheochromocytoma with a Tumor-Developing Mutation in the RET Gene.

Authors:  Haremaru Kubo; Yuya Tsurutani; Takashi Sunouchi; Yoshitomo Hoshino; Rei Hirose; Sho Katsuragawa; Noriko Kimura; Jun Saito; Tetsuo Nishikawa
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

2.  Anesthesia and Outcome of 33 Surgeries in 24 Multiple Endocrine Neoplasia Type 2A (MEN2A) Patients: A National Rare Disease Center's Experience.

Authors:  Yaohan Li; Di Jin; Le Shen; Yuguang Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.